1
|
Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, Mumm CD, Hallford HG, Mulvihill JJ. Cancer chemotherapeutic agents as human teratogens. ACTA ACUST UNITED AC 2012; 94:626-50. [DOI: 10.1002/bdra.23063] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Revised: 06/29/2012] [Accepted: 07/04/2012] [Indexed: 12/11/2022]
|
2
|
Abstract
Cervical and ovarian cancers are the most common gynaecological cancers diagnosed during pregnancy. In early-stage cervical cancer during the first and at the beginning of the second trimester, the two main considerations for management of the patient are the tumour size (and stage) and nodal staging. MRI and laparoscopic lymphadenectomy are useful for clinicians planning a potentially conservative approach. The management of patients with locally advanced cervical disease is controversial and should be discussed on a case-by-case basis according to the tumour size, radiological findings, the term of pregnancy, and the patient's wishes. Different histological types of malignant ovarian diseases arise during pregnancy and their management depends on the diagnosis (histological subtypes, tumour differentiation, and nodal status), the tumour stage, and the trimester of the pregnancy. In patients with peritoneal spread or high-risk early-stage disease, neoadjuvant chemotherapy with pregnancy preservation could be appropriate.
Collapse
Affiliation(s)
- Philippe Morice
- Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | |
Collapse
|
3
|
Nulman I, Edell H. Paediatric outcomes following in utero exposure to the diagnosis and treatment of maternal malignancy. Eur J Cancer 2011; 47 Suppl 3:S217-29. [DOI: 10.1016/s0959-8049(11)70168-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Pereg D, Lishner M. Maternal and fetal effects of systemic therapy in the pregnant woman with cancer. Recent Results Cancer Res 2008; 178:21-38. [PMID: 18080440 DOI: 10.1007/978-3-540-71274-9_3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Affiliation(s)
- D Pereg
- Department of Internal Medicine A, Meir Medical Center, Kfar Sava, Israel
| | | |
Collapse
|
5
|
Abstract
Chemotherapy may be indicated for the treatment of cancer during pregnancy. The decision to use chemotherapy significantly impacts the pregnancy, and in turn the pregnancy may affect the treatment options available to patients with cancer. This review provides information about the effects of chemotherapeutic agents in pregnancy, taking into account both the mother and the fetus. For convenience, the agents are divided into categories based upon class and mechanism of action. These include alkylating agents, antimetabolites, nucleoside analogs, topoisomerase I inhibitors, topisomerase II inhibitors, vinca alkaloids, taxanes, and biologics such as signaling and growth factor blocking agents.
Collapse
Affiliation(s)
- Kimberly K Leslie
- Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, 2211 Lomas Boulevard NE, Albuquerque NM 87131-0001, USA.
| | | | | |
Collapse
|
6
|
MESH Headings
- Antibiotics, Antineoplastic/pharmacology
- Antibiotics, Antineoplastic/therapeutic use
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antimetabolites, Antineoplastic/pharmacology
- Antimetabolites, Antineoplastic/therapeutic use
- Antineoplastic Agents/pharmacology
- Antineoplastic Agents/therapeutic use
- Antineoplastic Agents, Alkylating/pharmacology
- Antineoplastic Agents, Alkylating/therapeutic use
- Cytarabine/pharmacology
- Daunorubicin/pharmacology
- Daunorubicin/therapeutic use
- Doxorubicin/pharmacology
- Doxorubicin/therapeutic use
- Enzyme Inhibitors/pharmacology
- Enzyme Inhibitors/therapeutic use
- Etoposide/pharmacology
- Etoposide/therapeutic use
- Female
- Fetus/drug effects
- Humans
- Nucleic Acid Synthesis Inhibitors/pharmacology
- Nucleic Acid Synthesis Inhibitors/therapeutic use
- Paclitaxel/pharmacology
- Paclitaxel/therapeutic use
- Pregnancy
- Pregnancy Complications, Neoplastic/drug therapy
- Topotecan/pharmacology
- Topotecan/therapeutic use
- Trastuzumab
- Vinblastine/pharmacology
- Vinblastine/therapeutic use
- Vincristine/pharmacology
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- Kimberly K Leslie
- Department of Obstetrics and Gynecology, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA.
| |
Collapse
|
7
|
Otsuka K, Hamakawa H, Sumida T, Tanioka H. Treatment of mandibular malignant fibrous histiocytoma during pregnancy. J Oral Maxillofac Surg 2001; 59:220-4. [PMID: 11213995 DOI: 10.1053/joms.2001.20505] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K Otsuka
- Department of Oral and Maxillofacial Surgery, Ehime University School of Medicine, Japan
| | | | | | | |
Collapse
|
8
|
Merimsky O, Le Chevalier T, Missenard G, Lepechoux C, Cojean-Zelek I, Mesurolle B, Le Cesne A. Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester. Ann Oncol 1999; 10:345-50. [PMID: 10355581 DOI: 10.1023/a:1008235023749] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Ewing's sarcoma of the pelvic bones was diagnosed in a 21-year childbearing woman, raising major medical and ethical problems. The diagnostic and therapeutic approaches during the sixth month of gestation were tailored in order to cure the patient and avoid unnecessary toxicity to the fetus. Ancillary tests included ultrasound and MRI studies of the pelvis. Ifosfamide and adriamycin, premedicated by granisetron, were administered during gestation, and were found to be safe. Cesarean section was the preferred way of delivery since the tumor involved the pelvic bones. The outcome was a disease-free patient and a small healthy baby who is now two years of age.
Collapse
Affiliation(s)
- O Merimsky
- Unit of Bone and Soft Tissue Sarcoma, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
The information available concerning the effects of chemotherapy administered during pregnancy is limited and consists of case reports and small series. A registry has been established at the National Cancer Institute, but there are currently only several hundred cases of neonates exposed to chemotherapy registered. All clinicians who care for women receiving chemotherapy during pregnancy should report those experiences to the National Cancer Institute to increase the data base. When chemotherapy is used during the embryogenesis period in the first trimester there is an increased rate of spontaneous abortion and major birth defects. The most toxic chemotherapeutic agents administered during pregnancy are methotrexate and aminopterin and should be avoided when possible, particularly during the first trimester. Pregnancy-related physiologic changes should be kept in mind when dosing and administering cytotoxic chemotherapy. The risk of fetal malformation when chemotherapy is administered during the second and third trimesters is probably not greater than background rate, but there may be a greater risk of stillbirth, fetal growth restriction, premature birth, and maternal and fetal myelosuppression. Breastfeeding should be avoided in women receiving chemotherapy.
Collapse
Affiliation(s)
- J I Sorosky
- Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, USA
| | | | | |
Collapse
|
10
|
Abstract
BACKGROUND The natural histories of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) during pregnancy are not well understood. METHODS All cases of HD and NHL diagnosed during pregnancy at Stanford University Medical Center since 1987 were reviewed and clinical follow-up was obtained. Various immunohistochemical studies and in situ hybridization for Epstein-Barr virus (EBV) encoded RNA were performed in a subset of cases. RESULTS Seventeen cases of HD and 12 cases of NHL were accessioned (median age; 27 yrs). The HD cases were classified as 13 nodular sclerosis type, 3 mixed cellularity type, and 1 unclassified. Clinical follow-up revealed most of the patients had Stage II to III disease and were diagnosed on average at 22 weeks gestation. Most of the patients deferred therapy until after delivery and had no evidence of disease at the last follow-up except for one death with disease but not from it. NHL were classified according to the working formulation as high or intermediate grade lymphomas of various types, including both nodal and extranodal sites. Clinical follow-up revealed most had Stage II to IV disease and were diagnosed on average at 23 weeks gestation. Patients with HD tended to survive longer than those with NHL (raw mortality, P = 0.04). In situ hybridization failed to provide support for the presence of EBV in a subset of patients with NHL. CONCLUSIONS The clinical behavior of these neoplasms during pregnancy does not appear to be significantly different from that outside of the setting of pregnancy. Treatment of selected HD patients apparently may be safely deferred until after delivery. Patients with NHL present with higher stage disease and have a poorer prognosis than those with HD.
Collapse
MESH Headings
- Adolescent
- Adult
- Combined Modality Therapy
- Delivery, Obstetric
- Female
- Follow-Up Studies
- Gestational Age
- Herpesvirus 4, Human/genetics
- Hodgkin Disease/drug therapy
- Hodgkin Disease/pathology
- Hodgkin Disease/virology
- Humans
- Immunohistochemistry
- In Situ Hybridization
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/virology
- Neoplasm Staging
- Pregnancy
- Pregnancy Complications, Neoplastic/pathology
- Pregnancy Complications, Neoplastic/virology
- Prognosis
- RNA, Viral/genetics
- RNA, Viral/isolation & purification
- Retrospective Studies
- Survival Rate
Collapse
Affiliation(s)
- A B Gelb
- Department of Pathology, University of California, San Francisco 94143-0102, USA
| | | | | | | |
Collapse
|
11
|
Goldwasser F, Pico JL, Cerrina J, Fernandez H, Pons JC, Cosset JM, Hayat M. Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient. Leuk Lymphoma 1995; 20:173-6. [PMID: 8750642 DOI: 10.3109/10428199509054772] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We report a case of non-Hodgkin's lymphoma (NHL) successfully treated with combination chemotherapy during pregnancy. The histological diagnosis was large-cell B-type NHL. Four courses of chemotherapy with epirubicin, vincristine and prednisolone were given before delivery. The patient is in complete remission and her baby, now four years old, has developed normally. To our knowledge, this is the first reported case of epirubicin administration during pregnancy and in which chemotherapy was given safely to NHL patients during the second and third trimester of pregnancy.
Collapse
|
12
|
Abstract
Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poor, there is recent evidence to suggest that when properly treated, pregnancy does not affect the course of lymphoma. The risk to the fetus can also be reduced by an appropriate therapeutic approach.
Collapse
Affiliation(s)
- M Lishner
- Department of Medicine A, Meir Hospital Kfar-Saba, Israel
| | | | | | | |
Collapse
|
13
|
A model combining the whole embryo culture with human liver S-9 fraction for human teratogenic prediction. Toxicol In Vitro 1993; 7:827-31. [DOI: 10.1016/0887-2333(93)90087-l] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Abstract
A rare case of non-Hodgkin's lymphoma stage IE complicating pregnancy is presented. The diagnosis was made by biopsy at 28 weeks gestation and treated with 2635 rad of external radiotherapy with abdominal and pelvic shielding beginning at 30 weeks gestation. Following delivery, the patient received combination chemotherapy and is disease-free 6 years later. The baby, weighing 2015 g, was delivered by cesarean section at term. The effects of radiotherapy on a fetus are reviewed and the factors that were considered in the treatment of this patient are discussed. Radiotherapy with protective shielding can be an effective initial modality of treatment in this setting.
Collapse
Affiliation(s)
- M Spitzer
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, New York 11042
| | | | | | | |
Collapse
|
15
|
Avilés A, Díaz-Maqueo JC, Torras V, García EL, Guzmán R. Non-Hodgkin's lymphomas and pregnancy: presentation of 16 cases. Gynecol Oncol 1990; 37:335-7. [PMID: 2351317 DOI: 10.1016/0090-8258(90)90363-p] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Chemotherapy and obstetric care of 16 pregnant patients with non-Hodgkin's lymphoma are reported in this paper. All patients received chemotherapy during the various trimesters of pregnancy, including 8 cases during the first trimester, and there was no evidence of congenital malformations in any offspring. Fifteen babies are alive, healthy, and at a normal level of growth 3 to 11 years after birth. Eight mothers who achieved complete remission are alive and free of disease, 4 to 9 years after delivery, without maintenance treatment and would be considered cured. On the basis of the present study it was concluded that pregnancy is not a contraindication for treatment of non-Hodgkin's lymphomas, cytotoxic drugs do not necessarily cause congenital malformations, and long-term remission can be achieved in these mothers.
Collapse
Affiliation(s)
- A Avilés
- Department of Hematology, Oncology Hospital, National Medical Center, IMSS, Mexico City, Mexico
| | | | | | | | | |
Collapse
|
16
|
Nantel S, Parboosingh J, Poon MC. Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy. MEDICAL AND PEDIATRIC ONCOLOGY 1990; 18:143-5. [PMID: 1689451 DOI: 10.1002/mpo.2950180211] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Non-Hodgkin's lymphoma occurring during pregnancy is a rare event. A young woman at 18 weeks gestation with twins presented with a B-cell immunoblastic lymphoma. Combination chemotherapy with methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) was instituted after limited staging. There was excellent response and the 12 weekly chemotherapy protocol was completed in 13 weeks. Twin male infants were born at 28 weeks gestation by cesarean section for premature labor. There was no evidence of any congenital malformations or hematologic suppressions. We believe this to be the first report of aggressive weekly chemotherapy during pregnancy; this approach to treatment in aggressive non-Hodgkin's lymphoma is both efficacious and safe.
Collapse
Affiliation(s)
- S Nantel
- Department of Medicine, University of Calgary, Foothills Hospital, Alberta, Canada
| | | | | |
Collapse
|
17
|
Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellmann DB. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18:88-110. [PMID: 3064307 DOI: 10.1016/0049-0172(88)90002-9] [Citation(s) in RCA: 68] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- R Roubenoff
- Department of Medicine, Johns Hopkins University School of Medicine and Hospital, Baltimore, MD
| | | | | | | | | |
Collapse
|
18
|
Abstract
This article reports two cases and reviews the literature regarding chemotherapy using anthracyclines during pregnancy. Twenty-six additional cases using this class of agents to treat malignancy during pregnancy are summarized from 18 reports for a total of 28 pregnancies. Final outcome of pregnancy is analyzed with regard to the following factors: diagnosis, gestational age at start of therapy, total dose of anthracycline, number and type of agents used, neonatal pathologic findings and months of follow-up of infants. Final outcome of 28 pregnancies resulted in 24 normal infants including a set of twins in the current report. Limited pharmacokinetic information is inconclusive with regard to the appearance of anthracyclines and their known metabolites in placental or fetal tissue.
Collapse
Affiliation(s)
- J J Turchi
- Division of Medical Oncology, Mercy Catholic Medical Center, Darby, PA 19023
| | | |
Collapse
|
19
|
Shibuya H, Saiot M, Horiuchi JI, Suzuki S. Treatment of malignant head and neck tumors during pregnancy--a report of 3 cases. Acta Oncol 1987; 26:237-8. [PMID: 3651268 DOI: 10.3109/02841868709091439] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
20
|
Gulati SC, Vega R, Gee T, Koziner B, Clarkson B. Growth and development of children born to patients after cancer therapy. Cancer Invest 1986; 4:197-205. [PMID: 3719409 DOI: 10.3109/07357908609018449] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Eighteen children born to parents who had previously received chemotherapy or radiotherapy were examined for physical health, growth, and development. The immunologic and the hematologic status of these children was also evaluated. Their ages ranged from birth to 15 years. The children had a careful history and physical examination to detect any abnormal symptoms or signs, and the parent's previous treatment was carefully documented. Four sets of parents had children while one of the parents was on active treatment (2 male and 2 female). Of the male patients, one patient's wife had a baby that was "small for gestational age" at birth and had transient failure to thrive; the other child was normal. Of the female patients, one offspring was small for gestational age at birth and the other was normal, but both continued to have failure to thrive for up to 17 months and 26 months, respectively. Ten parents procreated after being treated with chemotherapy and/or radiotherapy, to whom 14 children were born. One child was a stillbirth with multiple congenital abnormalities, and another child had trisomy 13-15 and died 6 months later. The other 12 children were normal at birth, but one child is under the 5th percentile for growth at twelve months of age. In all children studied, immune function test, complete blood count, and viral titers were considered normal for age. In our study, we found that three out of four children born to parents who were on chemotherapy had failure to thrive. Of the 14 children born to parents who conceived after being off chemotherapy, 11 were found to be normal in growth and development. These results imply that there is a high risk of complications in children born to parents who procreated while receiving chemotherapy. Further studies are needed to develop better guidelines for counseling cancer patients who want to have children.
Collapse
|
21
|
Steiner-Salz D, Yahalom J, Samuelov A, Polliack A. Non-Hodgkin's lymphoma associated with pregnancy. A report of six cases, with a review of the literature. Cancer 1985; 56:2087-91. [PMID: 4027936 DOI: 10.1002/1097-0142(19851015)56:8<2087::aid-cncr2820560834>3.0.co;2-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Six patients with non-Hodgkin's lymphoma diagnosed during late pregnancy or shortly thereafter are reported. Three patients had high-grade lymphoma and three, intermediate-grade histologic features. Five of the six patients were in Stage 4 and one was Stage 1. Only three had the diagnosis of non-Hodgkin's lymphoma during pregnancy, and in these three cases the disease appeared to progress rapidly after delivery. The other three women probably had lymphoma during pregnancy; lymphoma was widespread at the time of their diagnosis, but the diagnosis was only established on biopsy specimens after delivery in all three instances. Five patients had full-term natural deliveries with normal infants. A single patient with Burkitt's lymphoma had a premature delivery with a cesarean section in the 29th week because of abruptio placentae probably due to lymphoma of the uterine wall. In this case both mother and child died within 48 hours of delivery. The other five patients were treated soon after delivery. Published literature dealing with this topic is scanty and inconclusive; accordingly this report attempts to discuss management of lymphoma in pregnancy, based on the authors' limited experience with these six patients.
Collapse
|
22
|
Abstract
A 21-year-old, gravida 1, para O, woman presented at approximately 25 weeks gestation with a large Ewing's sarcoma involving her iliac wing. She was treated with multiagent chemotherapy before a successful Cesarean delivery of a normal infant at approximately 34 weeks gestation. Four years later both the mother and child are doing well. The literature regarding sarcoma occurring during pregnancy and that regarding multiagent chemotherapy in pregnant patients is reviewed. Chemotherapy should be instituted early in the course of many malignant sarcomas, despite pregnancy, to prevent the occurrence of metastases.
Collapse
|
23
|
Talbot SF, Main DM, Levinson AI. Wegener's granulomatosis: first report of a case with onset during pregnancy. ARTHRITIS AND RHEUMATISM 1984; 27:109-12. [PMID: 6691851 DOI: 10.1002/art.1780270118] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
24
|
|
25
|
Lowenthal RM, Funnell CF, Hope DM, Stewart IG, Humphrey DC. Normal infant after combination chemotherapy including teniposide for Burkitt's lymphoma in pregnancy. MEDICAL AND PEDIATRIC ONCOLOGY 1982; 10:165-9. [PMID: 6175887 DOI: 10.1002/mpo.2950100211] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A 32-year-old woman was treated for Burkitt's lymphoma diagnosed during the 22nd week of pregnancy. Chemotherapy consisting of doxorubicin (Adriamycin), vincristine, teniposide (VM-26), cyclophosphamide, and prednisolone (AVTEP) was given each 2.5 to 3 weeks from the time of the diagnosis until delivery in the 37th week. Bleomycin and intrathecal methotrexate were also given from the 35th week. The infant was born after an assisted vaginal delivery and was fully developed and normal in all respects. This paper confirms prior reports that cytotoxic chemotherapy may safely be given during the second and third trimesters of pregnancy without adverse effects on the fetus. To our knowledge it is the first report of the use of teniposide, a new podophyllin derivative, during pregnancy.
Collapse
|
26
|
Abstract
Non-Hodgkin's lymphoma associated with pregnancy is rare. To date, only 1 case in which lymphoma was diagnosed and treated during pregnancy, with normal pregnancy outcome, has been reported. We describe another case where life-threatening, diffuse, poorly differentiated lymphocytic lymphoma was diagnosed during the 13th week of pregnancy. Combination chemotherapy (cyclophosphamide, vincristine, bleomycin, and prednisone) resulted in remission and a health full-term infant was born.
Collapse
|